Publications by authors named "S Zwillich"
Ritlecitinib is an oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma (JAK3/TEC) family kinase inhibitor approved for the treatment of severe alopecia areata (AA). Benefit-risk profiles of two doses of ritlecitinib (50 mg vs 30 mg once daily) were evaluated by integrating patient preferences and clinical efficacy and safety estimates for ritlecitinib. A discrete-choice experiment (DCE) was utilized to elicit preferences for benefit and safety attributes of systemic AA treatments.
View Article and Find Full Text PDFArticle Synopsis
- This study investigates the effectiveness and safety of ritlecitinib, a treatment for alopecia areata (AA), over 48 weeks in patients with varying responses by Week 24.
- Results showed that over 85% of patients who had good responses at Week 24 maintained their improvement, while some nonresponders also began to show better results by Week 48.
- The study had a small sample size, but it concludes that ritlecitinib can lead to sustained hair regrowth in many patients with AA.
Article Synopsis
- Ritlecitinib, a drug being tested for alopecia areata, caused reversible axonal swelling and auditory potential changes in dogs at doses higher than what's approved for humans.
- * A phase 2a study evaluated the effects of ritlecitinib on auditory and nerve fiber changes in 71 patients, comparing results with a placebo group over 9 months.
- * Findings showed no significant differences in auditory or nerve fiber measures between the treatment and placebo groups, suggesting that dog toxicity findings may not apply to human patients.
Article Synopsis
- - The study aimed to assess patient satisfaction with hair growth in people with alopecia areata (AA) receiving ritlecitinib or a placebo, focusing on how well patients felt their treatment was working compared to what clinicians observed.
- - In the ALLEGRO-2b/3 trial, 718 AA patients with significant scalp hair loss were given either ritlecitinib or a placebo for 24 weeks, after which some switched treatments; satisfaction was measured through a specific survey evaluating different aspects of hair growth.
- - Results showed that at week 24, satisfaction with hair growth was significantly higher in ritlecitinib groups (up to 67.5%) compared to placebo (22.6%),
Objectives: We characterised changes in absolute lymphocyte counts (ALCs) and lymphocyte subset counts (LSCs), and their relationship to incidence of serious infection events (SIEs) and herpes zoster (HZ) events in Japanese patients with moderate to severe rheumatoid arthritis enrolled in the tofacitinib clinical programme.
Methods: Data included 765 patients receiving tofacitinib in Phase 2, Phase 3, and long-term extension studies. ALCs/LSCs and incidence rates (patients with events/100 patient-years) of SIEs and HZ were analysed over 75 months.